GLUE (Monte Rosa Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is a publicly traded Healthcare sector company. As of May 21, 2026, GLUE trades at $18.62 with a market cap of $1.52B and a P/E ratio of 0.00. GLUE moved +6.09% today. Year to date, GLUE is +29.51%; over the trailing twelve months it is +348.32%. Its 52-week range spans $3.50 to $25.77. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces GLUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate GLUE?

7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $32.80.

GLUE Key Metrics

Key financial metrics for GLUE
MetricValue
Price$18.62
Market Cap$1.52B
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$25.77
52-Week Low$3.50
Volume6
Avg Volume0
Revenue (TTM)$75.62M
Net Income$-72.70M
Gross Margin0.00%

GLUE Analyst Consensus

7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.

Latest GLUE News

Recent GLUE Insider Trades

  • Warmuth Markus sold 5.47K (~$103.45K) on May 1, 2026.
  • Warmuth Markus sold 8.00K (~$141.12K) on Apr 14, 2026.
  • Nickson Philip sold 5.84K (~$103.41K) on Apr 9, 2026.

Common questions about GLUE

What do analysts rate GLUE?
7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $32.80.
Does Rallies show GLUE price targets?
Yes. Rallies tracks GLUE analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is GLUE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GLUE. It does not provide personalized investment advice.
GLUE

GLUE